{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:44:24Z","timestamp":1784126664654,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Sotorasib and adagrasib have been widely used for the non-small cell lung cancer (NSCLC) patients harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation. It's necessary to assess their safety profiles in the real-world population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective pharmacovigilance was conducted to examine adverse events (AEs) associated with sotorasib and adagrasib therapies using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Disproportionality analysis was performed employing Venn analysis and four data-mining algorithms, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most commonly reported system organ classes (SOCs) for both adagrasib and sororasib were general, gastrointestinal, and investigations disorders. Notably, sotorasib exhibited significant signals for neoplasms and hepatobiliary disorders in four algorithms. Specifically, AEs related to neoplasms were predominantly associated with lung malignancies, all of which were consistent with the therapeutic indications of KRAS G12C mutation inhibitor. A total of 19 common AEs were identified in sotorasib and adagrasib, spanning gastrointestinal, general, hepatobiliary, investigations, metabolism, musculoskeletal, neoplasms, and respiratory disorders. 4 severe AEs (SAEs) were identified in sotorasib, with 3 SAEs displaying significant signals in four algorithms, including drug-induced liver injury, pancreatitis, and hepatic failure. In adagrasib, only 2 SAEs were detected, with renal failure showing significant signals in four algorithms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study offers a comprehensive evaluation of the major safety signals associated with sotorasib and adagrasib, providing valuable information for clinicians regarding drug selection and safety considerations, thereby facilitating the design of future prospective safety studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1418469","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:28:48Z","timestamp":1724819328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Lisha","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilinuer","family":"Aierken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12890-018-0660-2","article-title":"Risk factors for interstitial lung disease: a 9-year Nationwide population-based study","volume":"18","author":"Choi","year":"2018","journal-title":"BMC Pulm. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","article-title":"Brief report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-programmed cell death (Ligand)1 and sotorasib therapy in KRAS(G12C)-Mutant lung cancer","volume":"18","author":"Chour","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/17476348.2020.1766971","article-title":"Smoking-associated interstitial lung disease: update and review","volume":"14","author":"Dawod","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"105074","DOI":"10.1016\/j.ebiom.2024.105074","article-title":"Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis","volume":"102","author":"Ernst","year":"2024","journal-title":"EBioMedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1101861","DOI":"10.3389\/fphar.2023.1101861","article-title":"A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B9","unstructured":"Good pharmacovigilance practices and pharmacoepidemiologic assessment2005"},{"key":"B10","unstructured":"Questions and answers on FDA's adverse event reporting system (FAERS)2018"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S1309","DOI":"10.1016\/j.annonc.2023.10.066","article-title":"LBA65 KRYSTAL-7: efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na\u00efve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"34","author":"Garassino","year":"2023","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and opportunities in accessing and analysing FAERS data: a call towards a collaborative approach","volume":"46","author":"Giunchi","year":"2023","journal-title":"Drug. Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/pro.4125","article-title":"A structural perspective on targeting the RTK\/Ras\/MAP kinase pathway in cancer","volume":"30","author":"Heppner","year":"2021","journal-title":"Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a G12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare"},{"key":"B18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0018578718795271","article-title":"The newly available FAERS public dashboard: implications for health care professionals","volume":"54","author":"Kumar","year":"2019","journal-title":"Hosp. Pharm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"100261","DOI":"10.1016\/j.jtocrr.2021.100261","article-title":"Clinical characteristics and outcomes in advanced KRAS-mutated NSCLC: a multicenter collaboration in Asia (ATORG-005)","volume":"3","author":"Lee","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","article-title":"The KRAS-G12C inhibitor: activity and resistance","volume":"29","author":"Liu","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2300644","DOI":"10.1200\/PO.23.00644","article-title":"Adagrasib treatment after sotorasib-related hepatotoxicity in patients with KRAS(G12C)-Mutated non-small cell lung cancer: a case series and literature review","volume":"8","author":"Luo","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"B23","unstructured":"English2024"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3390\/cancers13061204","article-title":"Targeting KRAS in cancer: promising therapeutic strategies","volume":"13","author":"Mustachio","year":"2021","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40264-016-0450-9","article-title":"Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas","volume":"39","author":"Shah","year":"2016","journal-title":"Drug. Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2300030","DOI":"10.1200\/PO.23.00030","article-title":"Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer","volume":"7","author":"Thummalapalli","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1126\/science.1062023","article-title":"The guanine nucleotide-binding switch in three dimensions","volume":"294","author":"Vetter","year":"2001","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1158\/0008-5472.CAN-20-3991","article-title":"Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"106080","DOI":"10.1016\/j.isci.2023.106080","article-title":"Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"key":"B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4251\/wjgo.v5.i5.97","article-title":"RAS signaling pathways, mutations and their role in colorectal cancer","volume":"5","author":"Zenonos","year":"2013","journal-title":"World J. Gastrointest. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","article-title":"Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1418469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:28:52Z","timestamp":1724819332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1418469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":35,"alternative-id":["10.3389\/fphar.2024.1418469"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1418469","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"article-number":"1418469"}}